Published in Int J Nanomedicine on January 01, 2006
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol (2002) 17.41
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
The natural history of chronic allograft nephropathy. N Engl J Med (2003) 8.70
Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med (2003) 8.47
Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol (2002) 8.04
Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science (1996) 5.92
Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol (2002) 5.37
GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell (2003) 5.21
A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci U S A (2001) 4.16
Immunopharmacology of rapamycin. Annu Rev Immunol (1996) 3.86
Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet (2002) 3.68
TOR signaling. Sci STKE (2003) 3.61
Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med (2003) 3.61
Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J (2004) 3.29
mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. Genes Dev (2004) 2.96
Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet (2000) 2.81
Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc (2003) 2.71
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res (2004) 2.64
Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu Rev Immunol (2004) 2.59
United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans (2003) 2.34
Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation (1996) 2.24
Control of nutrient-sensitive transcription programs by the unconventional prefoldin URI. Science (2003) 2.15
Immunophilin-sensitive protein phosphatase action in cell signaling pathways. Cell (1992) 2.08
Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation (2005) 1.94
A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol Cell Biol (2004) 1.88
Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation (2001) 1.85
Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int (2003) 1.83
Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc Natl Acad Sci U S A (2000) 1.77
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol (2006) 1.73
Cardiovascular toxicities of immunosuppressive agents. Am J Transplant (2002) 1.71
Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res (2003) 1.69
Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol (2001) 1.57
mTOR integrates amino acid- and energy-sensing pathways. Biochem Biophys Res Commun (2004) 1.54
Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant (2005) 1.53
Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation (2003) 1.46
A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation (2001) 1.41
The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation (2003) 1.40
Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation (1994) 1.39
Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem (2003) 1.36
Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. J Biol Chem (2003) 1.35
The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int (1988) 1.34
Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood (2003) 1.33
Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation (2002) 1.33
The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci (1993) 1.30
Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med (1986) 1.29
Target of rapamycin (TOR)-signaling and RAIP motifs play distinct roles in the mammalian TOR-dependent phosphorylation of initiation factor 4E-binding protein 1. J Biol Chem (2003) 1.29
Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation (2002) 1.26
Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp Cell Res (2004) 1.25
Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int (1996) 1.22
Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol (2001) 1.17
Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol (2004) 1.12
Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant (2004) 1.12
Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-gamma is regulated by mammalian target of rapamycin. J Biol Chem (2003) 1.07
Amino acids as regulators of gene expression at the level of mRNA translation. J Nutr (2003) 1.05
Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation (2002) 1.04
Disease-specific questionnaire for patients with a renal transplant. Nephron (1993) 1.04
Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest (1993) 0.98
Raptor, a binding partner of target of rapamycin. Biochem Biophys Res Commun (2004) 0.98
Ser-64 and Ser-111 in PHAS-I are dispensable for insulin-stimulated dissociation from eIF4E. J Biol Chem (2003) 0.97
Distribution of sirolimus in rat tissue. Clin Biochem (1997) 0.97
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int (2005) 0.97
Translational regulation of terminal oligopyrimidine mRNAs induced by serum and amino acids involves distinct signaling events. J Biol Chem (2004) 0.96
Influence of immunosuppressive drugs on dendritic cells. Transpl Immunol (2003) 0.96
Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int (1996) 0.96
Rapamycin-resistant proliferation of CD8+ T cells correlates with p27kip1 down-regulation and bcl-xL induction, and is prevented by an inhibitor of phosphoinositide 3-kinase activity. J Biol Chem (2003) 0.95
CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin. J Biol Chem (1994) 0.95
Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int (2004) 0.94
Immunosuppressants: cellular and molecular mechanisms of action. Am J Kidney Dis (1996) 0.94
Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation (2003) 0.94
Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int (1997) 0.93
Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest (1991) 0.92
Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: role of sodium intake. J Am Soc Nephrol (1993) 0.92
Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int Suppl (1995) 0.92
Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation (1997) 0.91
A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. The Canadian Multicentre Transplant Study Group. N Engl J Med (1986) 0.91
A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases. Kidney Int (1998) 0.90
Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A. Lab Invest (1988) 0.90
Cyclosporine nephrotoxicity in cardiac allograft patients--a seven-year follow-up. Transplantation (1990) 0.90
Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant (2004) 0.88
Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc (2003) 0.88
Health-related quality-of-life outcomes of sirolimus-treated kidney transplant patients after elimination of cyclosporine A: results of a 2-year randomized clinical trial. Transplantation (2003) 0.86
Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients. Kidney Int (1995) 0.86
Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat. Nephrol Dial Transplant (2003) 0.85
A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation (2003) 0.84
Compared to mycophenolate mofetil, rapamycin induces significant changes on growth factors and growth factor receptors in the early days post-kidney transplantation. Transplantation (2002) 0.83
Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation (2004) 0.83
Do we know the site of action of cyclosporin? Immunol Today (1992) 0.83
Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation (2005) 0.81
The effect of cyclosporine on early graft function in human renal transplantation. Transplantation (1983) 0.80
Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. Kidney Int (1994) 0.80
Differential translation of TOP mRNAs in rapamycin-treated human B lymphocytes. Biochim Biophys Acta (2003) 0.80
Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients. Transpl Int (1991) 0.78
A self-administered quality of life questionnaire for renal transplant recipients. Nephron (1998) 0.78
Renal transplant morphology after long-term therapy with cyclosporine. Transplant Proc (1995) 0.77
Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-beta1. Transplantation (2004) 0.77
Cyclosporine-associated nephropathy in patients with heart and bone marrow transplants. Clin Nephrol (1988) 0.77
Rapamycin increases transforming growth factor-beta mRNA expression in immortalized rat proximal renal tubular cells. Transplantation (2002) 0.76